New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
09:08 EDTSNY, ALNYAlnylam deal with Sanofi positive, says JMP Securities
After Alnylam (ALNY) announced that Sanofi (SNY) would buy a 12% stake in it, while the two companies will enhance their cooperation, JMP Securities believes the deal provides Alnylam with significant pipeline and platform leverage. The firm also believes that the deal reduces the company's risk and increases its potential return;. JMP Securities reiterates an Outperform rating on the stock.
News For ALNY;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
14:03 EDTSNYSanofi initiated with a Buy at HSBC
Subscribe for More Information
June 23, 2015
16:18 EDTALNYAlnylam weakness a buying opportunity, says Deutsche Bank
Deutsche Bank said Alnylam's Phase 1 AT-3 conference presentation update was positive, as expected, supporting safety and efficacy. The firm's analyst said weakness could be due to fast money selling and recommends buying shares on weakness.
14:31 EDTALNYAlnylam reports new positive clinical data for ALN-AT3
Subscribe for More Information
June 15, 2015
08:06 EDTSNYGenzyme initiates Phase 1/2 olipudase alfa clinical trial
Subscribe for More Information
05:36 EDTALNYAlnylam price target raised to $180 from $155 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for shares of Alnylam Pharmaceuticals to $180 after the company reported preliminary Phase I ALN-CC5 data at the European Hematology Association meeting. Hemolysis was lowered by an average of 43% with a max knockdown of 61% after a single dose, making ALN-CC5 the company's fourth RNAi drug to achieve human proof-of-concept, Tenthoff pointed out. He views Alnylam as an emerging orphan drug play with multiple potential blockbusters and reiterates an Overweight rating on the name. The stock closed Friday down $2.46 to $130.28.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use